Journal
EMERGING INFECTIOUS DISEASES
Volume 12, Issue 4, Pages 631-637Publisher
CENTERS DISEASE CONTROL & PREVENTION
DOI: 10.3201/eid1204.050960
Keywords
-
Categories
Funding
- NIAID NIH HHS [R01 AI40481-01A1] Funding Source: Medline
- PHS HHS [R01 CCR523379] Funding Source: Medline
Ask authors/readers for more resources
We performed a prospective study of all inpatient and outpatient methicillin-resistant Staphylococcus aureus (MRSA) isolates identified at the University of Chicago Hospitals from November 2003 through November 2004. Differences in resistance to non-p-lactam antimicrobial drugs were determined after stratification of the 578 MRSA isolates into 4 groups by patient age (pediatric vs. adult) and onset location (community vs. hospital). Non-p-lactam resistance was significantly greater among the 288 adult than the 177 pediatric community-associated isolates for erythromycin (93.2 vs. 87.0%, p = 0.03), clindamycin (51.8 vs. 7.3%, p < 0.001), ciprofloxacin (62.1 vs. 10.7%, p < 0.001), gentamicin (11.1 vs. 1.1%, p < 0.001), and tetracycline (119.9 vs. 6.4%, p < 0.001). In contrast, hospital-associated MRSA isolates from children and adults had similar rates of non-p-lactam antimicrobial drug resistance. In our region, clindamycin is an appropriate empiric therapy of community-associated MRSA infection in children but should be used with caution in adults.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available